Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 3;7(72):eabq2791.
doi: 10.1126/sciimmunol.abq2791. Epub 2022 Jun 3.

ILC2s-Bipartisan politicians in cancer

Abderezak Zebboudj  1   2 , Masataka Amisaki  1   2 , Vinod P Balachandran  1   2   3   4
Affiliations
Comment

ILC2s-Bipartisan politicians in cancer

Abderezak Zebboudj et al. Sci Immunol. .

Abstract

Group 2 innate lymphoid cells (ILC2s) are lymphocytes that both promote and suppress antitumor immunity. Jou and colleagues now report in colorectal tumorigenesis that the cytokine interleukin-25 activates ILC2s to induce myeloid cells that suppress antitumor immunity.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Schematic of select pro and anti-tumor functions of ILC2s in cancer. IL-33-activates ILC2s to produce chemokines that induce NK cells and CD8+ T cells to indirectly, and cytokines to directly suppress cancer. In contrast, IL-25 activates ILC2s to produce cytokines that stimulate myeloid cells and eosinophils to promote cancer. MDSC – Myeloid Derived Suppressor Cell; NK – Natural Killer.
See this image and copyright information in PMC

Comment on

References

    1. Jou E, Rodriguez-Rodriguez N, Ferreira A-CF, Jolin HE, Clark PA, Sawmynaden K, Ko M, Murphy JE, Mannion J, Ward C, Matthews DJ, Buczacki SJA, McKenzie ANJ, An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc-mutation-driven intestinal tumorigenesis. Science Immunology. - PMC - PubMed
    1. Saranchova I, Han J, Zaman R, Arora H, Huang H, Fenninger F, Choi KB, Munro L, Pfeifer CG, Welch I, Takei F, Jefferies WA, Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis. Sci Rep-uk 8, 2924 (2018). - PMC - PubMed
    1. Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, Gönen M, Leach SD, Wolchok JD, DeMatteo RP, Merghoub T, Balachandran VP, ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature 579, 130–135 (2020). - PMC - PubMed
    1. Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, Kouro T, Itakura A, Nagai Y, Takaki S, Takatsu K, Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity. J Immunol 188, 703–713 (2012). - PubMed
    1. Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J, Souza-Fonseca-Guimaraes F, de Graaf CA, Thia K, Macdonald S, Camilleri M, Luong K, Zhang S, Chopin M, Molden-Hauer T, Nutt SL, Umansky V, Ciric B, Groom JR, Foster PS, Hansbro PM, McKenzie ANJ, Gray DHD, Behren A, Cebon J, Vivier E, Wicks IP, Trapani JA, Munitz A, Davis MJ, Shi W, Neeson PJ, Belz GT, Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol 22, 851–864 (2021). - PMC - PubMed

Publication types